Germany Benign Prostatic Hyperplasia Treatment Market Size, Share, Growth, and Industry Analysis, By Treatment Type (Pharmacological treatmentAlpha-blockersTamsulosinSilodosinAlfuzosinDoxazosinOther alpha-blockers5-alpha reductase inhibitors (5-ARI)DutasterideFinasterideCombination therapyAlpha-blockers + 5-arisAlpha-blockers + pde5 inhibitorsPhosphodiesterase-5 inhibitors (pde5 inhibitors)Herbal and other drugs, Surgical treatmentTransurethral resection of the prostate (TURP)Transurethral incision of the prostate (TUIP)Open prostatectomyLaser therapyHolmium laser enucleation of the prostate (HOLEP)Photoselective vaporisation of the prostate (PVP), Minimally invasive proceduresUrolift systemRezūm water vapour therapyProstatic artery embolisationMicrowave thermotherapyTransurethral needle ablation (TUNA), Other treatmentsLifestyle modificationsWatchful waiting / active surveillance), By End Use (Hospitals, Clinics, Ambulatory surgical centres, Specialty urology centers) and Forecast, 2026-2034

Table of Contents

1. Executive Summary
   1. Introduction
2. Market Introduction
   1. Market Definition
   2. Scope of the Study
   3. Market Structure
3. Research Methodology
   1. Primary Research
   2. Research Methodology
   3. Assumptions & Exclusions
   4. Secondary Data Sources
4. Market Factor Analysis
   1. Value Chain Analysis: Germany Benign Prostatic Hyperplasia Treatment Market
   2. Porters Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitution
      4. Threat of New Entrants
      5. Competitive Rivalry
5. Market Dynamics
   1. Drivers
   2. Restraints
   3. Opportunities
6. Recent Trends Analysis
7. Impact of COVID-19 on Germany Benign Prostatic Hyperplasia Treatment Market
   1. Pre and Post Covid -19 Market Scenario Analysis
   2. Market Recovery Timeline and Challenge
   3. Measures Taken by Top Players
8. Regulatory Landscape
9. Germany Benign Prostatic Hyperplasia Treatment Market, By Type
   1. Introduction
      1. Market Size and Forecast, By Type
   2. Drugs
      1. Market Size and Forecast, By Region
   3. Devices
      1. Market Size and Forecast, By Region
   4. Surgery
      1. Market Size and Forecast, By Region
10. Germany Benign Prostatic Hyperplasia Treatment Market, By Application
    1. Introduction
       1. Market Size and Forecast, By Application
    2. Monotherapy
       1. Market Size and Forecast, By Region
    3. Combination Therapy
       1. Market Size and Forecast, By Region
11. Germany Benign Prostatic Hyperplasia Treatment Market, By Distribution Channel
    1. Introduction
       1. Market Size and Forecast, By Distribution Channel
    2. Hospital Pharmacies
       1. Market Size and Forecast, By Region
    3. Retail Pharmacies
       1. Market Size and Forecast, By Region
    4. Online Pharmacies
       1. Market Size and Forecast, By Region
12. Regional Overview
    1. Introduction
       1. Market Size and Forecast
    2. Germany
       1. Market Size and Forecast
          1. By Type
             1. Drugs
             2. Devices
             3. Surgery
          2. By Application
             1. Monotherapy
             2. Combination Therapy
          3. By Distribution Channel
             1. Hospital Pharmacies
             2. Retail Pharmacies
             3. Online Pharmacies
13. Competitive Landscape, 2025
    1. Introduction
    2. Germany Benign Prostatic Hyperplasia Treatment Market Share Analysis, 2025 (%)
       1. Market Share Analysis, 2025
       2. Competition Ranking, 2025
       3. Key Developments & Growth Strategies
          1. Merger & Acquisition
          2. Product Launch
          3. Expansion
       4. Consolidated SWOT Analysis of Key Players
14. Company Profile
    1. Bayer AG
       1. Business Overview
       2. Financial Data
       3. Key Product domains
       4. Recent Developments
    2. AstraZeneca plc (Germany Operations)
    3. GlaxoSmithKline plc (Germany Operations)
    4. Pfizer Inc. (Germany Operations)
    5. Sanofi S.A. (Germany Operations)
    6. Eli Lilly and Company (Germany Operations)
    7. Teva Pharmaceutical Industries Ltd. (Germany Operations)
    8. Boston Scientific Corporation (Germany Operations)
    9. Medtronic plc (Germany Operations)
    10. Olympus Corporation (Germany Operations)
    11. Karl Storz SE & Co. KG
    12. Procept BioRobotics Corporation (Germany Operations)
    13. NeoTract, Inc. (Teleflex Incorporated Germany)
    14. Urologix, LLC (Germany Operations)
    15. Richard Wolf GmbH